69 results
S-8
EX-99.2
we7heuh
20 Feb 24
Registration of securities for employees
4:16pm
S-8
EX-99.3
3ssgt7rp3 31vvfflg
20 Feb 24
Registration of securities for employees
4:16pm
S-8
EX-99.1
w526pt 5kih71t
20 Feb 24
Registration of securities for employees
4:16pm
8-K
EX-10.23
bojk8a3z
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.21
y25t0 ihej
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.6
2pto2
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.22
lk1b lk9e
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-99.4
b5c4244645qt5c5gstrv
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.3
fmi cjdjsye5y
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.2
kgehvjkfs9xwfox x8o
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.24
jibxo5hspolvj25lo
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
425
xpa0qv1g1sj lem8
4 Dec 23
Business combination disclosure
5:14pm
8-K
EX-10.1
ftnnr8xt118c3tsx1
4 Dec 23
Other Events
5:10pm